2023
Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial
Grilo C, Lydecker J, Jastreboff A, Pittman B, McKee S. Naltrexone/bupropion for binge‐eating disorder: A randomized, double‐blind, placebo‐controlled trial. Obesity 2023, 31: 2762-2773. PMID: 37751990, PMCID: PMC10600891, DOI: 10.1002/oby.23898.Peer-Reviewed Original ResearchMeSH KeywordsBinge-Eating DisorderBulimiaBupropionDouble-Blind MethodFemaleHumansMaleMiddle AgedNaltrexoneObesityTreatment OutcomeWeight LossConceptsNaltrexone/bupropionBinge-eating disorderObesity statusLogistic regressionWeight lossPlacebo-controlled trialWeight loss outcomesPrevalent psychiatric disordersEvidence-based treatmentsPost-treatment assessmentBinge-eating frequencyGreater percentage weight lossMedication outcomesRemission ratePharmacological optionsPlaceboBupropionPsychiatric disordersPercentage weight lossMixed modelsDisordersObesityPatientsSignificant reductionWeight reduction
2022
Using machine learning to predict heavy drinking during outpatient alcohol treatment
Roberts W, Zhao Y, Verplaetse T, Moore KE, Peltier MR, Burke C, Zakiniaeiz Y, McKee S. Using machine learning to predict heavy drinking during outpatient alcohol treatment. Alcohol Clinical And Experimental Research 2022, 46: 657-666. PMID: 35420710, PMCID: PMC9180421, DOI: 10.1111/acer.14802.Peer-Reviewed Original ResearchMeSH KeywordsAlcoholismAlgorithmsEthanolFemaleHumansMachine LearningMaleOutpatientsTreatment OutcomeConceptsAlcohol use disorderHeavy drinkingTreatment outcomesInvasive assessment methodsOutpatient AUD treatmentLast monthOutpatient alcohol treatmentMultisite clinical trialAccurate clinical predictionsHeavy alcohol useSex differencesBi-weekly sessionsAlcohol treatment outcomesPatient characteristicsClinical outcomesClinical trialsClinical dataStratified analysisEffective treatmentPsychiatric disordersUse disordersAUD treatmentSubstantial sex differencesAlcohol treatmentFirst month
2019
Pharmacokinetics and Pharmacodynamics of Immediate-Release Versus Extended-Release Guanfacine in Adult Daily Smokers.
Verplaetse TL, Roberts W, Moore KE, Peltier MR, Oberleitner LM, McKee SA. Pharmacokinetics and Pharmacodynamics of Immediate-Release Versus Extended-Release Guanfacine in Adult Daily Smokers. Journal Of Clinical Psychopharmacology 2019, 39: 124-128. PMID: 30707118, PMCID: PMC6391212, DOI: 10.1097/jcp.0000000000001004.Peer-Reviewed Original ResearchConceptsAdult daily smokersDoses of guanfacineAdverse eventsMedication levelsDaily smokersTobacco cravingTreatment-emergent adverse eventsExtended-release formulationSimilar pharmacokinetic profileAttention deficit hyperactivity disorderDry mouthLast doseMigraine prophylaxisBlood pressureHeroin withdrawalStable dosingDose equivalencyHeart rateER formulationSmoking outcomesGuanfacinePharmacokinetic profileDrug AdministrationVital signsHyperactivity disorderAlcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder
Verplaetse TL, Ralevski E, Roberts W, Gueorguieva R, McKee SA, Petrakis IL. Alcohol Abstainer Status and Prazosin Treatment in Association with Changes in Posttraumatic Stress Disorder Symptoms in Veterans with Comorbid Alcohol Use Disorder and Posttraumatic Stress Disorder. Alcohol Clinical And Experimental Research 2019, 43: 741-746. PMID: 30698839, PMCID: PMC6443463, DOI: 10.1111/acer.13969.Peer-Reviewed Original ResearchConceptsAlcohol use disorderPosttraumatic stress disorderPlacebo-treated individualsTotal CAPS scoresClinical trialsCAPS scoresPrazosin treatmentComorbid populationPTSD symptomsUse disordersClinician-Administered PTSD Scale scoresDouble-blind clinical trialStress disorderComorbid alcohol use disorderPrazosin-treated groupSymptoms of PTSDRecent clinical trialsComorbid alcohol dependenceCourse of treatmentΑ1-adrenergic antagonistPosttraumatic stress disorder (PTSD) symptomsOngoing symptomsSleep disturbancesMedication effectsNoradrenergic system
2018
Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking
Roberts W, Ralevski E, Verplaetse TL, McKee SA, Petrakis IL. Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking. Journal Of Substance Use And Addiction Treatment 2018, 94: 91-96. PMID: 30243424, PMCID: PMC6154389, DOI: 10.1016/j.jsat.2018.08.015.Peer-Reviewed Original ResearchConceptsAlcohol use disorderClinical trialsSmoking outcomesNicotinic acetylcholine receptor antagonistAlcohol useHigh-dependence smokersEffects of mecamylamineSubgroups of smokersAcetylcholine receptor antagonistHigh tobacco dependencePlacebo groupMedication conditionReceptor antagonistMedication effectsTobacco dependenceTobacco useTreatment respondersMecamylamineSmokingTreatment phaseUse disordersAlcohol dependenceSmokersTrialsSignificant differencesEffects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users
Roberts W, Shi JM, Tetrault JM, McKee SA. Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users. Journal Of Addiction Medicine 2018, 12: 227-233. PMID: 29438157, PMCID: PMC5970035, DOI: 10.1097/adm.0000000000000392.Peer-Reviewed Original ResearchConceptsLow-dose naltrexoneTobacco usersTreatment outcomesPlacebo-controlled human laboratory studySmoking cessation treatmentEffects of vareniclineCigarettes ad libitumHuman laboratory studiesSubjective drug effectsVarenicline monotherapyCessation medicationsMedication therapyCessation treatmentMedication armTobacco useVareniclineLow doseSmoking relapseSmokingDrug effectsSmoking outcomesSmoking behaviorNaltrexoneCarbon monoxide levelsHeavy drinkers
2016
Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis
Smith PH, Weinberger AH, Zhang J, Emme E, Mazure CM, McKee SA. Sex Differences in Smoking Cessation Pharmacotherapy Comparative Efficacy: A Network Meta-analysis. Nicotine & Tobacco Research 2016, 19: 273-281. PMID: 27613893, PMCID: PMC5939704, DOI: 10.1093/ntr/ntw144.Peer-Reviewed Original ResearchConceptsTransdermal nicotineSmoking cessationBupropion SRComparative efficacyFirst option treatmentSustained release bupropionPlacebo-controlled trialSex differencesCigarette smoking cessationNetwork Meta-AnalysisRelease bupropionCessation pharmacotherapyOption treatmentGeneral community sampleCigarette smokersQuit ratesVarenicline's efficacyPharmacological interventionsVareniclineBupropionNicotine addictionMeta-AnalysisPlaceboSimilar outcomesSignificant sex differencesModafinil and sleep architecture in an inpatient–outpatient treatment study of cocaine dependence
Morgan PT, Angarita GA, Canavan S, Pittman B, Oberleitner L, Malison RT, Mohsenin V, Hodges S, Easton C, McKee S, Bessette A, Forselius E. Modafinil and sleep architecture in an inpatient–outpatient treatment study of cocaine dependence. Drug And Alcohol Dependence 2016, 160: 49-56. PMID: 26777774, PMCID: PMC4767553, DOI: 10.1016/j.drugalcdep.2015.12.004.Peer-Reviewed Original ResearchConceptsUrine toxicology screenModafinil treatmentSlow-wave sleepClinical outcomesOutpatient treatmentToxicology screenUrine screensInpatient settingInpatient treatmentSleep timeCocaine dependencePrimary clinical outcomeWeekly cognitive behavioral therapyCocaine usersImproved clinical outcomesPolysomnographic sleep recordingsChronic cocaine useChronic cocaine usersHigh rateCognitive behavioral therapyCocaine-dependent participantsSleep architectureOutpatient phaseEffective treatmentDays abstinent
2015
Antidepressant-like effects of guanfacine and sex-specific differences in effects on c-fos immunoreactivity and paired-pulse ratio in male and female mice
Mineur YS, Bentham MP, Zhou WL, Plantenga ME, McKee SA, Picciotto MR. Antidepressant-like effects of guanfacine and sex-specific differences in effects on c-fos immunoreactivity and paired-pulse ratio in male and female mice. Psychopharmacology 2015, 232: 3539-3549. PMID: 26146014, PMCID: PMC4561580, DOI: 10.1007/s00213-015-4001-3.Peer-Reviewed Original ResearchConceptsAntidepressant-like effectsPaired-pulse ratioC-Fos immunoreactivityPrefrontal cortexSwim testBrain areasRobust antidepressant-like effectsBrain regionsSex differencesMale C57BL/6J miceDepression-like behaviorEffects of guanfacineAcetylcholinesterase inhibitor physostigmineLight/dark boxBaseline sex differencesC-fos expressionDepression-like stateCritical brain regionsDifferent brain areasSex-specific changesAntidepressant efficacyCholinergic controlInhibitor physostigmineC57BL/6J miceAgonist guanfacineA Randomized Trial for Hazardous Drinking and Smoking Cessation for Callers to a Quitline
Toll BA, Martino S, O’Malley S, Fucito LM, McKee SA, Kahler CW, Rojewski AM, Mahoney MC, Wu R, Celestino P, Seshadri S, Koutsky J, Hyland A, Cummings KM. A Randomized Trial for Hazardous Drinking and Smoking Cessation for Callers to a Quitline. Journal Of Consulting And Clinical Psychology 2015, 83: 445-454. PMID: 25419583, PMCID: PMC5996380, DOI: 10.1037/a0038183.Peer-Reviewed Original ResearchMeSH KeywordsAdultAlcoholismCounselingFemaleHotlinesHumansMaleMiddle AgedNew YorkSmokingSmoking CessationTobacco Use DisorderTreatment OutcomeConceptsStandard careHazardous drinkingHigher smoking cessation ratesNew York State Smokers' QuitlineHeavy drinkingBrief motivational counselingSmoking cessation ratesState Smokers' QuitlineBrief alcohol interventionTelephone coachesCessation counselingTreat analysisCessation ratesRandomized trialsTelephone quitlinesCessation successSmoking cessationAcceptable adherenceMotivational counselingQuitlineAlcohol interventionsAlcohol useCareSmokersDrinking
2012
Two Decades of Smoking Cessation Treatment Research on Smokers with Depression: 1990–2010
Weinberger AH, Mazure CM, Morlett A, McKee SA. Two Decades of Smoking Cessation Treatment Research on Smokers with Depression: 1990–2010. Nicotine & Tobacco Research 2012, 15: 1014-1031. PMID: 23100459, PMCID: PMC3693502, DOI: 10.1093/ntr/nts213.Peer-Reviewed Original ResearchConceptsRelationship of depressionSmoking cessation outcomesCessation outcomesSmoking cessationTreatment outcomesCurrent major depressive disorderMajor depressive disorderCurrent depression symptomsClinical trialsDepressive disorderMinor depressionMajor depressionInclusion criteriaMEDLINE searchPast diagnosisTreatment approachesDepression symptomsHealth-related risksMajority of studiesPotential articlesDepressionRacial differencesOutcomesCessationSmokersDeveloping and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation
McKee SA, Weinberger AH, Shi J, Tetrault J, Coppola S. Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation. Nicotine & Tobacco Research 2012, 14: 1362-1371. PMID: 22492085, PMCID: PMC3482010, DOI: 10.1093/ntr/nts090.Peer-Reviewed Original ResearchConceptsSubsequent ad libitum smokingSmoking cessation medicationsAd libitum smokingCessation medicationsNicotine deprivationSmoking cessationNovel smoking cessation medicationsRatings of cravingSmoking lapse behaviorHuman laboratory modelSecondary outcomesClinical efficacyClinical findingsFirst cigaretteMedication effectsSmokingMedication developmentCigarette effectsMedicationsLapse behaviorSmoking lapseTranslational toolScreen medicationsMonetary reinforcementTranslational workEffects of Varenicline and Bupropion on Cognitive Processes Among Nicotine-Deprived Smokers
Ashare RL, McKee SA. Effects of Varenicline and Bupropion on Cognitive Processes Among Nicotine-Deprived Smokers. Experimental And Clinical Psychopharmacology 2012, 20: 63-70. PMID: 21942262, PMCID: PMC3640636, DOI: 10.1037/a0025594.Peer-Reviewed Original ResearchConceptsNicotine deprivationCognitive processesMeasures of attentionNicotine-deprived smokersMeasures of cravingEffects of vareniclineNegative affectOvernight abstinenceCurrent data highlightMemoryReduced accuracyDaily smokersCurrent sampleDifficulty concentratingLaboratory sessionsEffects of bupropionFuture researchReaction timeSex differencesRecent researchAbstinence ratesDeficitsNew pharmacological treatmentsParticipantsSmoking cessation
2010
Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion
Mazure CM, Toll B, McKee SA, Wu R, O’Malley S. Menstrual cycle phase at quit date and smoking abstinence at 6 weeks in an open label trial of bupropion. Drug And Alcohol Dependence 2010, 114: 68-72. PMID: 20832955, PMCID: PMC3016455, DOI: 10.1016/j.drugalcdep.2010.07.024.Peer-Reviewed Original ResearchMeSH KeywordsAdultBupropionFemaleFollicular PhaseHumansLuteal PhaseMenstrual CycleSmokingSmoking CessationTime FactorsTreatment OutcomeConceptsMenstrual cycle phaseQuit datePoint prevalence abstinencePremenopausal womenBupropion SRFollicular phaseLuteal phaseAbsence of pharmacotherapySustained release bupropionOpen-label trialCycle phaseMechanism of actionRelease bupropionLabel trialNicotine replacementCessation interventionsOpen trialTreatment completionCessation outcomesContinuous abstinenceQuit dayGonadal hormonesTreatment periodAbstinence outcomesQuit attemptsChanges in smoking expectancies in abstinent, reducing, and non-abstinent participants during a pharmacological trial for smoking cessation
Weinberger AH, McKee SA, George TP. Changes in smoking expectancies in abstinent, reducing, and non-abstinent participants during a pharmacological trial for smoking cessation. Nicotine & Tobacco Research 2010, 12: 937-943. PMID: 20644207, PMCID: PMC2928936, DOI: 10.1093/ntr/ntq120.Peer-Reviewed Original ResearchConceptsNegative affect reductionNegative physical feelingsWeight control beliefsNon-abstinent participantsSmoking status interactionSmoking expectanciesNegative affectSmoking cessation treatmentControl beliefsSmoking beliefsSmoking cessation trialPoint prevalence abstinenceSocial facilitationBaseline expectanciesEnd of treatmentSocial interactionSmoking treatmentCessation outcomesQuit attemptsAbstinence outcomesCessation treatmentPhysical feelingsGender differencesCessation trialBeliefsQuitting smoking and change in alcohol consumption in the International Tobacco Control (ITC) Four Country Survey
Kahler CW, Borland R, Hyland A, McKee SA, O’Connor R, Fong GT, Cummings KM. Quitting smoking and change in alcohol consumption in the International Tobacco Control (ITC) Four Country Survey. Drug And Alcohol Dependence 2010, 110: 101-107. PMID: 20227840, PMCID: PMC2885485, DOI: 10.1016/j.drugalcdep.2010.02.008.Peer-Reviewed Original ResearchConceptsAlcohol consumptionInternational Tobacco Control Four Country SurveySmoking cessationFour Country SurveyAlcohol useHeavy drinkingSustained smoking cessationProspective cohort studyGreater reductionCohort studyHeaviness of smokingFrequent heavy drinkingDecreased oddsQuit attemptsSmokingHazardous drinkingCountry SurveyStudy wavesCessationDrinkingLower ratesAlcohol dataWeekly quantityMeaningful changePresent study
2008
Message Framing for Smoking Cessation: The Interaction of Risk Perceptions and Gender
Toll BA, Salovey P, O'Malley SS, Mazure CM, Latimer A, McKee SA. Message Framing for Smoking Cessation: The Interaction of Risk Perceptions and Gender. Nicotine & Tobacco Research 2008, 10: 195-200. PMID: 18188760, PMCID: PMC2527723, DOI: 10.1080/14622200701767803.Peer-Reviewed Original ResearchConceptsMessage framing interventionsRisk of cessationSmoking cessationLung cancerClinical trialsGain-framed messagesHigh riskSmoking relapseHealth message framingHealth problemsLoss-framed messagesSmokingFraming interventionCessationNumber of daysInfluence of genderInterventionRiskRisk perceptionWomenMedian splitGain-framed conditionDaysMenGender differences
2007
Enhancing brief cognitive-behavioral therapy with motivational enhancement techniques in cocaine users
McKee SA, Carroll KM, Sinha R, Robinson JE, Nich C, Cavallo D, O’Malley S. Enhancing brief cognitive-behavioral therapy with motivational enhancement techniques in cocaine users. Drug And Alcohol Dependence 2007, 91: 97-101. PMID: 17573205, PMCID: PMC2386854, DOI: 10.1016/j.drugalcdep.2007.05.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultCocaine-Related DisordersCognitive Behavioral TherapyDemographyFemaleHumansMaleMotivationPsychotherapy, BriefTreatment OutcomeConceptsCognitive behavioral therapyMotivational enhancement therapyBrief cognitive behavioral therapyMotivational enhancement techniquesSpecific treatment componentsCocaine usersExpectations of successMotivational interviewing techniquesCBT conditionCocaine useEnhancement therapyTreatment componentsIntervention paradigmInterviewing techniquesTherapy processMixed supportCocaine abuseInitial sessionTreatment retentionThree-sessionGreater desireGreat difficultyTreatment conditionsTreatment sessionsProcess measuresNaltrexone and Cognitive Behavioral Coping Skills Therapy for the Treatment of Alcohol Drinking and Eating Disorder Features in Alcohol‐Dependent Women: A Randomized Controlled Trial
O'Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, Rounsaville BJ, Wu R. Naltrexone and Cognitive Behavioral Coping Skills Therapy for the Treatment of Alcohol Drinking and Eating Disorder Features in Alcohol‐Dependent Women: A Randomized Controlled Trial. Alcohol Clinical And Experimental Research 2007, 31: 625-634. PMID: 17374042, DOI: 10.1111/j.1530-0277.2007.00347.x.Peer-Reviewed Original ResearchMeSH KeywordsAdaptation, PsychologicalAdultAlcohol DrinkingAlcoholismAttitudeBody Mass IndexBulimiaCognitive Behavioral TherapyCombined Modality TherapyDepressionFeeding and Eating DisordersFemaleGamma-GlutamyltransferaseHumansNaltrexoneNarcotic AntagonistsPsychiatric Status Rating ScalesTreatment OutcomeConceptsCognitive Behavioral Coping Skills TherapyAlcohol-dependent womenEfficacy of naltrexoneCoping skills therapyAlcohol dependenceOutpatient research clinicSkills therapyCo-occurring psychiatric conditionsEating Disorder FeaturesDSM-IV criteriaPercentage of participantsPrimary outcomeControlled TrialsAlcohol drinkingMedication conditionResearch clinicNaltrexonePsychiatric conditionsSecondary analysisImportant gender differencesTotal abstinenceHeavy drinkingPathologyWomenDrinking outcomes
2006
A Controlled Trial of Naltrexone Augmentation of Nicotine Replacement Therapy for Smoking Cessation
O’Malley S, Cooney JL, Krishnan-Sarin S, Dubin JA, McKee SA, Cooney NL, Blakeslee A, Meandzija B, Romano-Dahlgard D, Wu R, Makuch R, Jatlow P. A Controlled Trial of Naltrexone Augmentation of Nicotine Replacement Therapy for Smoking Cessation. JAMA Internal Medicine 2006, 166: 667-674. PMID: 16567607, DOI: 10.1001/archinte.166.6.667.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousAdministration, OralAmbulatory CareDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHumansLinear ModelsMaleMiddle AgedNaltrexoneNarcotic AntagonistsNicotineNicotinic AgonistsSmoking CessationSubstance Withdrawal SyndromeSurveys and QuestionnairesTreatment OutcomeWeight GainConceptsNicotine patch therapyNicotine patchPatch therapyDouble-blind placebo-controlled trialHigher continuous abstinence ratesLow-dose naltrexone therapyNaltrexone hydrochlorideWeight gainTreatment completersOral naltrexone hydrochlorideOutpatient research centerWeight-concerned smokersContinuous abstinence ratesPlacebo-controlled trialPrimary end pointSecond-line treatmentNicotine replacement therapyNaltrexone augmentationNaltrexone therapyPlacebo groupQuit dateTreat analysisAbstinence ratesReplacement therapySmoking cessation